Cocrystal Pharma, Inc.
COCP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001412486
No open-market purchases or sales by Cocrystal Pharma, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.17M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:04 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 31, 2025 | Mar 28, 2024 | – | Mar 23, 2022 |
| Operating expenses | $9.02M | $17.9M | $18.6M | $38.8M | $14.2M |
| Research and development | $5.05M | $12.5M | $15.2M | $12.4M | $8.79M |
| Selling, general and administrative | $3.96M | $5.34M | $5.99M | $5.75M | $5.43M |
| Operating income | -$9.02M | -$17.9M | -$18.6M | -$38.8M | -$14.2M |
| Interest expense | – | – | -$640.0K | $2.00K | $4.00K |
| Net income | -$8.83M | -$17.5M | -$18.0M | -$38.8M | -$14.2M |
| EPS, basic | $-0.78 | $-1.72 | $-1.87 | $-4.77 | – |
| EPS, diluted | $-0.78 | $-1.72 | $-1.87 | – | – |
| Weighted shares, basic | 11.3M | 10.2M | 9.65M | 8.14M | – |
| Weighted shares, diluted | 11.3M | 10.2M | 9.65M | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 31, 2025 | Mar 28, 2024 | – | Mar 23, 2022 |
| Cash and equivalents | $7.03M | $9.86M | $26.4M | $37.2M | $58.7M |
| Total current assets | $8.13M | $11.6M | $29.1M | $40.2M | $59.3M |
| Property, plant and equipment | $93.0K | $153.0K | $271.0K | $342.0K | $453.0K |
| Goodwill | – | – | – | – | $19.1M |
| Total assets | $9.71M | $13.5M | $31.3M | $40.8M | $79.4M |
| Accounts payable | $890.0K | $1.54M | $1.22M | $614.0K | $578.0K |
| Total current liabilities | $2.21M | $2.43M | $3.26M | $1.22M | $1.54M |
| Total liabilities | $3.38M | $3.93M | $4.88M | $1.27M | $1.84M |
| Shareholders' equity | $6.33M | $9.52M | $26.4M | $39.6M | $77.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 31, 2025 | Mar 28, 2024 | – | Mar 23, 2022 |
| Operating cash flow | -$8.19M | -$16.5M | -$14.7M | -$21.4M | -$12.7M |
| Capital expenditures | $12.0K | $8.00K | $118.0K | $74.0K | $52.0K |
| Free cash flow | -$8.20M | -$16.5M | -$14.8M | -$21.5M | -$12.8M |
| Depreciation and amortization | $72.0K | $126.0K | $189.0K | $185.0K | $190.0K |
| Stock-based compensation | $270.0K | $643.0K | $801.0K | $855.0K | $724.0K |
| Investing cash flow | -$12.0K | -$8.00K | -$118.0K | -$74.0K | -$52.0K |
| Financing cash flow | $5.37M | – | $3.99M | -$27.0K | $38.5M |
| Net change in cash | -$2.83M | -$16.5M | -$10.8M | -$21.5M | $25.7M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 13, 2026 | 19.3M | +87.8% | SEC |
| May 15, 2026 | 13.8M | +35.5% | SEC |
| Mar 24, 2026 | 13.8M | +35.5% | SEC |
| Nov 14, 2025 | 13.8M | +35.5% | SEC |
| Aug 12, 2025 | 10.3M | +0.8% | SEC |
| May 15, 2025 | 10.2M | 0.0% | SEC |
| Mar 31, 2025 | 10.2M | 0.0% | SEC |
| Nov 13, 2024 | 10.2M | 0.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-12 in Q4 2022.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.